TGTX
TG Therapeutics Inc.
$34.78
+$0.76(+2.23%)
55
Overall
20
Value
90
Tech
55
Quality
Market Cap
$5.14B
Volume
3.26M
52W Range
$22.92 - $46.48
Target Price
$43.57
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $152.4K | $152.4K | $152.0K | $152.0K | $152.0K | $152.0K | $6.7M | $2.8M | $233.7M | $329.0M | ||
| Total Revenue | $152.4K | $152.0K | $152.0K | $152.0K | $152.0K | $152.0K | $6.7M | $2.8M | $233.7M | $329.0M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | $790.0K | $265.0K | $14.1M | $38.5M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $152.4K | $152.4K | $152.0K | $152.0K | $152.0K | $152.0K | $5.9M | $2.5M | $219.5M | $290.5M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-63.3M | $-79.1M | $-118.9M | $-174.6M | $169.2M | $273.7M | $351.5M | $176.2M | $161.0M | $206.0M | ||
| Research & Development | $47.7M | $69.2M | $102.5M | $159.4M | $142.4M | $138.0M | $198.5M | $112.1M | $63.2M | $83.1M | ||
| Research Expense | $43.4M | $66.5M | $96.9M | $149.8M | $142.4M | $138.0M | $198.5M | $112.1M | $63.2M | $83.1M | ||
| Selling, General & Administrative | $15.6M | $9.9M | $16.3M | $15.2M | $4.0M | $-24.8M | $90.9M | $64.0M | $97.8M | $122.9M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | $41.5M | $90.9M | $64.0M | $97.8M | $122.9M | ||
| General & Administrative Expenses | $15.6M | $9.9M | $16.3M | $15.2M | $4.0M | $-66.3M | $840.0K | $367.0K | -- | -- | ||
| Salaries & Wages | $-15.7M | $-7.5M | $-15.9M | $-12.9M | $11.3M | $80.3M | $61.3M | -- | -- | -- | ||
| Amortization | -- | -- | -- | -- | $772.0K | $925.0K | $1.1M | $1.8M | $2.4M | $2.0M | ||
| Other Operating Expenses | $-63.3M | $-79.1M | $-118.9M | $-174.6M | $2.7M | $2.7M | $2.2M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-63.2M | $-79.0M | $-118.7M | $-174.4M | $-169.1M | $-273.6M | $-344.8M | $-192.8M | $20.6M | $41.9M | ||
| EBITDA | $-62.4M | $-77.7M | $-118.3M | $-172.5M | $-146.5M | $-272.7M | $-342.0M | $-183.1M | $30.4M | $49.9M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $972.7K | -- | -- | $877.0K | $5.3M | $6.3M | $5.6M | $10.2M | $12.6M | $24.0M | ||
| Intinc | $174.7K | $323.0K | $295.0K | $857.0K | -- | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $174.7K | $323.0K | $295.0K | $-877.0K | $-5.3M | $-6.3M | $-5.6M | $-10.2M | $-12.6M | $-24.0M | ||
| Gain on Sale of Securities | -- | $3.3K | $35.0K | $10.0K | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-56.7K | $-393.2K | $59.0K | $-1.8M | $-1.5M | $-542.0K | $-2.3M | $4.7M | $-5.0M | $-7.7M | ||
| Other Special Charges | $56.7K | $393.2K | $-59.0K | $1.8M | $1.5M | $542.0K | $2.3M | $4.7M | $5.0M | $7.7M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-62.9M | $-78.3M | $-118.5M | $-172.6M | $-147.3M | $-273.1M | $-342.5M | $-188.1M | $25.7M | $49.6M | ||
| Pre-Tax Income | $-62.9M | $-78.3M | $-118.5M | $-173.5M | $-150.0M | $-118.8M | $-286.0M | $-198.3M | $13.1M | $25.6M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-5.8M | -- | $-8.2M | $-639.0K | $-36.3M | $-58.7M | $-73.1M | $-41.6M | $390.0K | $2.2M | ||
| NET INCOME | ||||||||||||
| Net Income | $-62.9M | $-78.3M | $-118.5M | $-173.5M | $-172.9M | $-279.4M | $-348.1M | $-198.3M | $12.7M | $23.4M | ||
| Net Income (Continuing Operations) | $-62.9M | $-78.3M | $-118.5M | $-173.5M | $-172.9M | $-279.4M | $-348.1M | $-198.3M | $12.7M | $23.4M | ||
| Net Income (Discontinued Operations) | $-62.9M | $-78.3M | $-118.5M | $-173.5M | $-172.9M | $-279.4M | $-348.1M | $-198.3M | $12.7M | $23.4M | ||
| Net Income (Common Stockholders) | $-62.9M | $-78.3M | $-118.5M | $-173.5M | $-150.0M | $-279.4M | $-348.1M | $-198.3M | $12.7M | $23.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $25.3M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-63.3M | $-79.1M | $-118.9M | $-174.6M | $169.2M | $273.7M | $351.5M | $176.4M | $175.1M | $244.5M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $45.6M | $49.0M | $62.1M | $75.5M | $88.4M | $115.3M | $132.2M | $135.4M | $142.0M | $145.3M | ||
| Average Shares Outstanding (Diluted) | $45.6M | $48.9M | $62.0M | $75.4M | $88.4M | $115.3M | $132.2M | $135.4M | $148.5M | $160.3M | ||
| Shares Outstanding | $54.1M | $56.9M | $75.6M | $83.9M | $109.4M | $140.6M | $142.8M | $146.4M | $154.4M | $157.1M | ||
| Basic EPS | -- | -- | -- | -- | $-1.96 | $-2.42 | $-2.63 | $-1.46 | $0.09 | $0.16 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-1.96 | $-2.42 | $-2.63 | $-1.46 | $0.09 | $0.16 | ||
| Diluted EPS | $-1.38 | $-1.6 | $-1.91 | $-2.3 | $-1.96 | $-2.42 | $-2.63 | $-1.46 | $0.09 | $0.15 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-1.46 | $0.09 | $0.15 | ||
| OTHER METRICS | ||||||||||||
| Development Expense | $4.3M | $2.7M | $5.6M | $9.6M | -- | -- | -- | -- | -- | -- | ||
| Fees | $38.1K | $38.1K | $38.1K | -- | -- | -- | -- | -- | -- | -- | ||
| Interest Expense Operating | -- | -- | -- | -- | $-2.6M | $-4.5M | $-3.5M | -- | -- | -- | ||
| Minority Interests | -- | -- | -- | -- | $38.6M | $519.4M | -- | -- | -- | -- | ||
| Other Gand A | $15.6M | $9.9M | $16.3M | $15.2M | $4.0M | $-66.3M | $840.0K | $367.0K | -- | -- | ||
| Rent And Landing Fees | $-300.0K | $-1.6M | $-1.4M | $-1.4M | $2.7M | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TGTX | $34.78 | +2.2% | 3.26M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |